SynthesisFrontiers in oncology2026
Prognostic significance of inflammation-based markers in nasopharyngeal carcinoma: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory-Hematological Profiles in Nasopharyngeal Carcinoma and Suspicious Adenoid Hypertrophy: An Exploratory Single-Center Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation plays a pivotal role in tumor progression and prognosis. In nasopharyngeal carcinoma (NPC), several hematologic markers derived from systemic inflammation have emerged as potential prognostic indicators. This study aims to evaluate the prognostic value of inflammation-based indices in NPC systematically. Methods: A systematic review and meta-analysis were conducted according to PRISMA 2020 and MOOSE guidelines. A comprehensive search of PubMed, Embase, Scopus, and Web of Science was performed to identify eligible studies from January 2015 to December 2025. Nine studies involving 2, 986 NPC patients were included. Biomarkers assessed included the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for overall survival (OS) and progression-free survival (PFS). Results: Elevated inflammation-based markers were significantly associated with poor prognosis in NPC. The pooled HR for OS was 1.86 (95% CI: 1.42-2.43), and for PFS was 1.74 (95% CI: 1.31-2.30). Among individual markers, SII and SIRI showed the strongest associations with poor outcomes (HR = 2.01 and 1.93, respectively). In contrast, a higher LMR was associated with better prognosis (HR = 0.72, 95% CI: 0.53-0.98). Sensitivity and subgroup analyses confirmed the robustness and consistency of findings. No significant publication bias was detected. Conclusion: Systemic inflammation-based biomarkers, particularly SII and SIRI, are strong, independent predictors of survival in NPC. Their integration into clinical practice may enhance prognostic stratification and inform treatment decisions. Future prospective studies are warranted to validate these findings and standardize biomarker thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.